April 11, 2024Open Access

Waiting for new medicines in Canada, Europe, and the United States

BSBrett SkinnerCanadian Institute for Health Information

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

TITLE Waiting for new medicines in Canada, Europe, and the United States 2018-2023 CURRENT CONTRIBUTORS Brett Skinner, PhD, Canadian Health Policy Institute (CHPI) ATTRIBUTION This paper is corporately authored and edited based on proprietary template models and methods that are

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Brett Skinner (Thu,) studied this question.

synapsesocial.com/papers/68e6f962b6db643587673710 https://doi.org/https://doi.org/10.54194/qqvc3893

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Public v private insurance coverage for new drugs in Canada, 2018-2023, 7th EditionPublic v private insurance coverage for new drugs in Canada, 2018-2023, 7th Edition2024 · 1 citations
2Editorial: Volume 2: real world evidence (RWE): paths to enhancing patient access to new medications2026
3Patented Medicines Expenditure in Canada 1990–2022 8TH Edition2024
4The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study2024 · 4 citations
5Is Canada Moving towards a More Agile Regulatory Approval and a Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?2024 · 1 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo